Nové možnosti léčby glioblastoma multiforme
| Title in English | New therapeutic options in therapy of glioblastoma multiforme |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | glioblastoma multiforme; targeted therapy; biomarkers; angiogenesis; VEGF; EGFR; integrins |
| Description | Glioblastoma multiforme is one of the most aggressive malignant brain tumours with limited therapeutics options. Standard therapy is maximal surgical resection and adjuvant concurrent chemo- radiotherapy and maintenance therapy with temozolomide. This approach improves median and 5-year survival in comparison with postsurgical radiotherapy alone. Additional predictive and prognostic bio markers are necessary, especially due to the development of targeted therapy – antibodies and tyrosine kinase inhibitors. These new therapeutic approaches are under intensive investigation. The most promising data currently available are for anti-angiogenic therapies, such as bevacizumab and cediranib. This review presents a summary of the possible role of targeted therapy in the treatment of glioblastoma multiforme. |